Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Hiroki Ochiai, Takashi Ohishi, Koji Osumi, Jo Tokuyama, Hidejirou Urakami, Shikou Seki, Atsushi Shimada, Akira Matsui, Yoh Isobe, Yuya Murata, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Sumio Matsumoto, Yuukou Kitagawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. Methods: S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). Results: S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%). Conclusion: The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

Original languageEnglish
Pages (from-to)164-168
Number of pages5
JournalSurgery Today
Volume42
Issue number2
DOIs
Publication statusPublished - 2012 Jan

Fingerprint

Tumor Biomarkers
Colorectal Neoplasms
Antibodies
Serum
Carcinoembryonic Antigen
Carbohydrates
Lymphoid Tissue
Health Insurance
Colonic Neoplasms
Lymph Nodes
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis

Keywords

  • Colorectal cancer
  • Serum p53 antibody
  • Tumor marker

ASJC Scopus subject areas

  • Surgery

Cite this

Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. / Ochiai, Hiroki; Ohishi, Takashi; Osumi, Koji; Tokuyama, Jo; Urakami, Hidejirou; Seki, Shikou; Shimada, Atsushi; Matsui, Akira; Isobe, Yoh; Murata, Yuya; Endo, Takashi; Ishii, Yoshiyuki; Hasegawa, Hirotoshi; Matsumoto, Sumio; Kitagawa, Yuukou.

In: Surgery Today, Vol. 42, No. 2, 01.2012, p. 164-168.

Research output: Contribution to journalArticle

Ochiai, H, Ohishi, T, Osumi, K, Tokuyama, J, Urakami, H, Seki, S, Shimada, A, Matsui, A, Isobe, Y, Murata, Y, Endo, T, Ishii, Y, Hasegawa, H, Matsumoto, S & Kitagawa, Y 2012, 'Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients', Surgery Today, vol. 42, no. 2, pp. 164-168. https://doi.org/10.1007/s00595-011-0044-1
Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surgery Today. 2012 Jan;42(2):164-168. https://doi.org/10.1007/s00595-011-0044-1
Ochiai, Hiroki ; Ohishi, Takashi ; Osumi, Koji ; Tokuyama, Jo ; Urakami, Hidejirou ; Seki, Shikou ; Shimada, Atsushi ; Matsui, Akira ; Isobe, Yoh ; Murata, Yuya ; Endo, Takashi ; Ishii, Yoshiyuki ; Hasegawa, Hirotoshi ; Matsumoto, Sumio ; Kitagawa, Yuukou. / Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. In: Surgery Today. 2012 ; Vol. 42, No. 2. pp. 164-168.
@article{01f4878228cd4cbebe8c914571dddf0d,
title = "Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients",
abstract = "Purpose: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. Methods: S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). Results: S-p53Ab was positive in 33.1{\%} of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7{\%}) was significantly higher than that of CEA (5.3{\%}) or CA19-9 (7.9{\%}). Conclusion: The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.",
keywords = "Colorectal cancer, Serum p53 antibody, Tumor marker",
author = "Hiroki Ochiai and Takashi Ohishi and Koji Osumi and Jo Tokuyama and Hidejirou Urakami and Shikou Seki and Atsushi Shimada and Akira Matsui and Yoh Isobe and Yuya Murata and Takashi Endo and Yoshiyuki Ishii and Hirotoshi Hasegawa and Sumio Matsumoto and Yuukou Kitagawa",
year = "2012",
month = "1",
doi = "10.1007/s00595-011-0044-1",
language = "English",
volume = "42",
pages = "164--168",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

AU - Ochiai, Hiroki

AU - Ohishi, Takashi

AU - Osumi, Koji

AU - Tokuyama, Jo

AU - Urakami, Hidejirou

AU - Seki, Shikou

AU - Shimada, Atsushi

AU - Matsui, Akira

AU - Isobe, Yoh

AU - Murata, Yuya

AU - Endo, Takashi

AU - Ishii, Yoshiyuki

AU - Hasegawa, Hirotoshi

AU - Matsumoto, Sumio

AU - Kitagawa, Yuukou

PY - 2012/1

Y1 - 2012/1

N2 - Purpose: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. Methods: S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). Results: S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%). Conclusion: The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

AB - Purpose: We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. Methods: S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). Results: S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%). Conclusion: The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

KW - Colorectal cancer

KW - Serum p53 antibody

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84857642977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857642977&partnerID=8YFLogxK

U2 - 10.1007/s00595-011-0044-1

DO - 10.1007/s00595-011-0044-1

M3 - Article

C2 - 22075664

AN - SCOPUS:84857642977

VL - 42

SP - 164

EP - 168

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 2

ER -